Leerink Partnrs Has Bearish Outlook for ALDX FY2028 Earnings

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Research analysts at Leerink Partnrs dropped their FY2028 earnings per share (EPS) estimates for Aldeyra Therapeutics in a research report issued on Wednesday, November 13th. Leerink Partnrs analyst M. Goodman now expects that the biotechnology company will post earnings per share of $2.50 for the year, down from their prior forecast of $2.55. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.48) per share.

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a report on Friday, August 9th.

Aldeyra Therapeutics Price Performance

NASDAQ:ALDX opened at $4.21 on Friday. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18. The company has a 50-day moving average of $5.45 and a 200 day moving average of $4.60. Aldeyra Therapeutics has a 1-year low of $2.43 and a 1-year high of $6.55.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, meeting the consensus estimate of ($0.25).

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. US Bancorp DE acquired a new stake in Aldeyra Therapeutics during the third quarter worth about $30,000. SG Americas Securities LLC purchased a new stake in shares of Aldeyra Therapeutics during the 2nd quarter worth $38,000. Paloma Partners Management Co acquired a new position in shares of Aldeyra Therapeutics during the 3rd quarter worth about $62,000. Diversified Trust Co purchased a new position in shares of Aldeyra Therapeutics in the 2nd quarter valued at $41,000. Finally, King Wealth Management Group increased its position in shares of Aldeyra Therapeutics by 24.5% during the third quarter. King Wealth Management Group now owns 13,700 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 2,700 shares in the last quarter. 59.71% of the stock is owned by institutional investors and hedge funds.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.